Limits...
Clinical Implications of iNOS Levels in Triple-Negative Breast Cancer Responding to Neoadjuvant Chemotherapy.

Jin Z, Wang W, Jiang N, Zhang L, Li Y, Xu X, Cai S, Wei L, Liu X, Chen G, Zhou Y, Liu C, Li Z, Jin F, Chen B - PLoS ONE (2015)

Bottom Line: One unique phenomenon is that inflammatory breast cancer is frequently triple negative.Our further in vitro studies confirmed that induction of proper levels of NO increased the resistance to cisplatin in triple-negative MDA-MB-231 cells.Moreover, iNOS/NO is considered as a potential target for combination therapy with platinum drugs for triple-negative breast cancer.

View Article: PubMed Central - PubMed

Affiliation: Department of Breast Surgery, The First Hospital of China Medical University, Shenyang, Liaoning, China.

ABSTRACT
Triple-negative breast cancer is a high-risk breast cancer with poor survival rate. To date, there is a lack of targeted therapy for this type of cancer. One unique phenomenon is that inflammatory breast cancer is frequently triple negative. However, it is still ambiguous how inflammation influences triple-negative breast cancer growth and responding to chemotherapy. Herein, we investigated the levels of inflammation-associated enzyme, iNOS, in 20 triple-negative breast cancer patients' tumors, and examined its correlation with patients' responses to platinum-based neoadjuvant chemotherapy. Our studies showed that triple-negative breast cancer patients with attenuated iNOS levels in tumor cells after treatment showed better responses to platinum-based neoadjuvant chemotherapy than other triple-negative breast cancer patients. Our further in vitro studies confirmed that induction of proper levels of NO increased the resistance to cisplatin in triple-negative MDA-MB-231 cells. Our data suggest that aberrant high level of iNOS/NO are associated with less effectiveness of platinum-based neoadjuvant chemotherapy in triple-negative breast cancer. Therefore, we propose to monitor iNOS levels as a new predictor for triple-negative breast cancer patient's response to platinum-based neoadjuvant chemotherapy. Moreover, iNOS/NO is considered as a potential target for combination therapy with platinum drugs for triple-negative breast cancer.

No MeSH data available.


Related in: MedlinePlus

Analysis of iNOS protein levels in TNBC patients by immunoblotting.
© Copyright Policy
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4510059&req=5

pone.0130286.g002: Analysis of iNOS protein levels in TNBC patients by immunoblotting.

Mentions: The clinical profiles of TNBC patients in this study are shown in Table 1. By employing IHC, we examined the expression of iNOS protein in human tumor tissues from 20 TNBC patients before and after platinum-based drugs neoadjuvant chemotherapy. Immunohistochemical examination showed iNOS was mainly located in the cytoplasm of TNBC cell (Fig 1). Furthermore, the expression of iNOS protein in patient’s tumor tissues was validated by immunoblotting (Fig 2).


Clinical Implications of iNOS Levels in Triple-Negative Breast Cancer Responding to Neoadjuvant Chemotherapy.

Jin Z, Wang W, Jiang N, Zhang L, Li Y, Xu X, Cai S, Wei L, Liu X, Chen G, Zhou Y, Liu C, Li Z, Jin F, Chen B - PLoS ONE (2015)

Analysis of iNOS protein levels in TNBC patients by immunoblotting.
© Copyright Policy
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4510059&req=5

pone.0130286.g002: Analysis of iNOS protein levels in TNBC patients by immunoblotting.
Mentions: The clinical profiles of TNBC patients in this study are shown in Table 1. By employing IHC, we examined the expression of iNOS protein in human tumor tissues from 20 TNBC patients before and after platinum-based drugs neoadjuvant chemotherapy. Immunohistochemical examination showed iNOS was mainly located in the cytoplasm of TNBC cell (Fig 1). Furthermore, the expression of iNOS protein in patient’s tumor tissues was validated by immunoblotting (Fig 2).

Bottom Line: One unique phenomenon is that inflammatory breast cancer is frequently triple negative.Our further in vitro studies confirmed that induction of proper levels of NO increased the resistance to cisplatin in triple-negative MDA-MB-231 cells.Moreover, iNOS/NO is considered as a potential target for combination therapy with platinum drugs for triple-negative breast cancer.

View Article: PubMed Central - PubMed

Affiliation: Department of Breast Surgery, The First Hospital of China Medical University, Shenyang, Liaoning, China.

ABSTRACT
Triple-negative breast cancer is a high-risk breast cancer with poor survival rate. To date, there is a lack of targeted therapy for this type of cancer. One unique phenomenon is that inflammatory breast cancer is frequently triple negative. However, it is still ambiguous how inflammation influences triple-negative breast cancer growth and responding to chemotherapy. Herein, we investigated the levels of inflammation-associated enzyme, iNOS, in 20 triple-negative breast cancer patients' tumors, and examined its correlation with patients' responses to platinum-based neoadjuvant chemotherapy. Our studies showed that triple-negative breast cancer patients with attenuated iNOS levels in tumor cells after treatment showed better responses to platinum-based neoadjuvant chemotherapy than other triple-negative breast cancer patients. Our further in vitro studies confirmed that induction of proper levels of NO increased the resistance to cisplatin in triple-negative MDA-MB-231 cells. Our data suggest that aberrant high level of iNOS/NO are associated with less effectiveness of platinum-based neoadjuvant chemotherapy in triple-negative breast cancer. Therefore, we propose to monitor iNOS levels as a new predictor for triple-negative breast cancer patient's response to platinum-based neoadjuvant chemotherapy. Moreover, iNOS/NO is considered as a potential target for combination therapy with platinum drugs for triple-negative breast cancer.

No MeSH data available.


Related in: MedlinePlus